Critical Care

Basilia Zingarelli, MD, PhD

Appointment

Associate Professor, Department of Pediatrics, University of Cincinnati College of Medicine

Email

basilia.zingarelli@cchmc.org

Phone

513-636-8704

Fax

513-636-4892

Bio

Basilia Zingarelli, M.D., Ph.D. graduated in July 1990 in Medicine at the University of Messina, Italy.

After attending for one year the fellowship program in Medical Toxicology, Dr. Zingarelli entered the graduate program in Experimental Medicine with special focus on Pharmacology at the University of Messina, Italy, where she obtained her Ph.D. degree in 1997.

During her graduate training from 1992 to 1993 Dr. Zingarelli studied the role of nitric oxide in hemorrhage and trauma at the Department of Experimental Pharmacology at the University “Federico II” of Naples in Italy.

From 1993 to 1995, she was invited as a visiting Research Associate at the Department of Physiology at the Medical University of South Carolina in Charleston in the laboratory of Dr. James A. Cook. Her research efforts focused on the pathophysiological mechanisms of sepsis and the innate immune processes that render patients susceptible or resistant to bacterial infections.

Dr. Zingarelli came to the University of Cincinnati in 1995 to continue her training as a post-doctoral fellow at the Division of Critical Care Medicine, at the Cincinnati Children’s Hospital, where she was promoted to Research Instructor in 1997.

Credentials

MD: School of Medicine, University of Messina, Italy, 1990.

PhD: Experimental Medicine, School of Medicine, University of Messina, Italy, 1997.

Residency: Medical Toxicology, School of Medicine, University of Messina, Italy, 1990-1992.

Fellowship: Research Fellow, Division of Critical Care Medicine, Children's Hospital Medical Center, Cincinnati, Ohio, 1995-1997.

Certification: General Medicine (Italian), 1990.

Position History

March 2007-present: Associate Professor of Pediatrics at Division of Critical Care Medicine, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
September 2003-March 2007: Research Associate Professor at Division of Critical Care Medicine, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
September 1999-August 2003: Research Assistant Professor at Division of Critical Care Medicine, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
October 1997-August 1999: Research Instructor at Division of Critical Care Medicine, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Awards and Honors

“Fondazione Bonino-Pulejo” Award, Messina-Italy. 1999
“Centro Nazionale delle Ricerche” Award, Rome-Italy. 1993
Travel Grant Award, 17th Annual Conference on Shock, Big Sky, Montana. 1994
Young Investigator Award (second place), 17th Annual Conference on Shock, Big Sky, Montana. 1994
“Società Italiana di Farmacologia” Award, Rome, Italy. 1995
“Centro Nazionale delle Ricerche” Award, Rome, Italy. 1995
Travel Grant Award, 18th Annual Conference on Shock, Asheville, North Carolina. 1995
Educational Scholarship Award, 33rd Critical Care Congress, Orlando, Florida. 2004
Annual Scientific Award, 33rd Critical Care Congress, Orlando, Florida. 2004
Shock Society and Editorial Board of SHOCK citation for outstanding contribution, 29th Annual Conference on Shock, Broomfield, Colorado. 2006
Annual Cell Biology Specialty Award, 38th Critical Care Congress, Nashville, Tennessee. 2009

Research

Signal transduction mechanisms regulating the inflammatory response in sepsis, hemorrhage, ischemia and reperfusion injury; inflammatory bowel disease with focus on the role of the nuclear enzyme poly (ADP-ribose) polymerase and the nuclear peroxisome proliferator activated receptors; development of novel therapeutic approaches for the treatment of sepsis and trauma

Research Grants and Contracts

National Institutes of Health R01 AG 027990 Mechanisms of Age-Related Inflammatory Response in Hemorrhagic Shock; Principal Investigator; September 1, 2007 - August 31, 2012

National Institutes of Health R01 GM 067202 Role of PPARgamma and PPARgamma Agonists in Septic Shock; Principal Investigator; July 1 2008 - June 30, 2013

National Institutes of Health R01 GM 027673 (Consortium with Medical University of South Carolina) Role of Eicosanoids In Shock; Co-Investigator; July 3, 2008 - June 30, 2014

Publications, Most Recent

Kaplan J, O’Connor M, Hake PW, Zingarelli B. Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration. Shock 23: 233-238, 2005.

Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-g is a new therapeutic target in sepsis and inflammation. Shock 23: 393-399, 2005.

Irazuzta J, Pretzlaff RK, Decourten-Myers G, Zemlan F, Zingarelli B. Dexamethasone decreases neurological sequelae and caspase activity.Intensive Care Med. 31: 146-150, 2005.

Fan H, Zingarelli B, Peck OM, Teti G, Tempel GE, Halushka PV, Spicher K, Boulay G, Birnbaumer L, Cook JA. Lipopolysaccharide and Gram-positive bacteria induced cellular inflammatory responses: role of heterotrimeric Ga1 proteins. Am. J. Physiol. Cell Physiol. 289: C293-301, 2005.

Kaplan J, Cook JA, Hake PW, O’Connor M, Burroughs T, Zingarelli B. 15-Deoxy-D12,14-prostaglandin J2 (15d-PGJ2), a peroxisome proliferator-activated receptor-g ligand, reduces tissue leukosequestration and mortality in endotoxic shock.Shock 24: 59-65, 2005.

Dixit SG, Zingarelli B, Buckley DJ, Buckley AR, Pauletti GM. Nitric oxide mediates increased P-glycoprotein activity in interferon-g-stimulated human intestinal cells. Am. J. Physiol. 288: G533-G540, 2005.

Okaya T, Blanchard J, Schuster R, Kuboki S, Husted T, Caldwell CC, Zingarelli B, Wong H, Solomkin JS, Lentsch AB. Age-dependent responses to hepatic ischemia/reperfusion injury.Shock 24: 421-427, 2005.

Duffy JY, Schwartz SM, Lyons JM, Bell JH, Wagner CJ, Zingarelli B, Pearl JM. Calpain inhibition attenuates endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. Crit. Care Med. 33: 623-628, 2005.

Zingarelli B. Nuclear factor-kB. Crit. Care Med. 33 (12 Suppl): S414-S416, 2005.

Fan H, Williams D, Breuel KF, Zingarelli B, Teti G, Tempel GE, Halushka PV, Cook JA. Gi proteins regulate lipopolysaccharide and Staphylococcus Aureus induced cytokine production but not (1Õ3)-Beta-D-glucan and induced cytokine suppression.Frontiers in Bioscience 11: 2264-2274, 2006.

Zingarelli B. Erythropoietin: a role in intensive care beyond erythropoiesis?Crit. Care Med. (editorial) 34: 1281-1282, 2006.

Peck OM, Zingarelli B, Fan H, Teti G, Tempel GE, Halushka PV, Cook JA. The phosphatidylinositol 3-kinase pathway regulates tolerance to lipopolysaccharide and priming responses to Staphylococcus Aureus and lipopolysaccharide. Shock 26: 31-36, 2006.

Piraino G, Cook JA, O’Connor M, Hake PW, Burroughs T, Teti D, Zingarelli B. Synergistic effect of peroxisome proliferator activated receptor g (PPARg) and liver x receptor-a (LXRa) in the regulation of inflammation in macrophages. Shock 26: 146-153, 2006.

Fan H, Williams DL, Zingarelli B, Breuel KF, Teti G, Tempel GE, Spicher K, Boulay G, Birnbaumer L, Halushka PV, Cook JA. Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in splenocytes by Gai proteins. Biochim. Biophys. Acta 1763: 1051-1058, 2006.

Zingarelli B, Hake PW, O’Connor M, Burroughs T, Piraino G, Denenberg A, Wong HR. Diverse cardioprotective signaling mechanisms of peroxisome proliferator activator receptor-g ligands, 15-deoxy-D12,14-PGJ2 and ciglitazone, in reperfusion injury: role of NF-kB, HSF-1 and Akt. Shock 28: 554-63, 2007.

Kaplan J, Cook JA, O’Connor M, Zingarelli B. Peroxisome proliferation-activated receptor g is required for the inhibitory effect of ciglitazone but not 15-deoxy-12,14-Prostaglandin J2 (15d-PGJ2) on the NF-kB pathway in human endothelial cells.Shock 28: 722-726, 2007.

Vish MG, Mangeshkar P, Piraino G, Denenberg A, Hake PW, O'Connor M, Zingarelli B. Proinsulin C-peptide exerts beneficial effects in endotoxic shock in mice. Crit. Care Med. 35: 1348-1355, 2007.

Wheeler DS, Lahni PM, Hake PW, Denenberg AG, Wong HR, Snead C, Catravas JD, Zingarelli B. The green tea polyphenol epigallocatechin-3-gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Shock 28: 353-359, 2007.

Fan H, Williams DL, Zingarelli B, Breuel KF, Teti G, Tempel GE, Spicher K, Boulay G, Birnbaumer L, Halushka PV, Cook JA. Differential regulation of lipopolysaccharide and gram-positive bacteria induced cytokine and chemokine production in macrophages by Ga_iproteins. Immunology 22: 116-23, 2007.

Giuliano JS Jr, Lahni PM, Harmon K, Wong HR, Doughty LA, Carcillo JA, Zingarelli B, Sukhatme VP, Parikh SM, Wheeler DS. Admission angiopoietin levels in children with septic shock.Shock 8: 650-654, 2007.

Chima R, Zingarelli B. Surfactant treatment of neonatal acute respiratory distress syndrome: Is “fortification” the answer? Crit. Care Med. 35: 2442-2443, 2007.

Zingarelli B, Fan H, Ashton S, Piraino G, Mangeshkar P, Cook JA. Peroxisome proliferation-activated receptor (PPAR) g is not necessary for the development of LPS-induced tolerance. Immunology 124: 51-57, 2008.

Abboud PA, Hake PW, Burroughs TJ, Odoms K, O'Connor M, Mangeshkar P, Wong HR, Zingarelli B. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur. J. Pharmacol. 579: 411-417, 2008.

Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Zingarelli B, Lentsch AB. Peroxisome proliferator-activated receptor-g protects against hepatic ischemia/reperfusion injury in mice.Hepatology 47: 215-224, 2008.

Wheeler DS, Lahni PM, Denenberg AG, Poynter SE, Wong HR, Cook JA, Zingarelli B. Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock 30: 267-273, 2008.

Irazuzta J, Pretzlaff RK, Decourten-Myers G, Zemlan F, Zingarelli B. Caspases inhibition decreases neurological sequelae in meningitis.Crit. Care Med. 36: 1603-1606; 2008.

Chima R, Hake P, Mangeshkar P, Piraino G, Denenberg A, Zingarelli B. Ciglitazone ameliorates lung inflammation by modulating the IKK/NF-kB pathway following hemorrhagic shock. Crit Care Med. 36: 2849-2857, 2008.

Basher F, Fan H, Zingarelli B, Borg KT, Louttrell LM, Tempel GE, Halushka PV, Cook JA.b-arrestin 2: a negative regulator of inflammatory responses in polymorphonuclear leukocytes. Int. J. Clin. Exp. Med. 1: 32-41, 2008.

Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA. Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol. Med. 14: 422-428, 2008.

Zingarelli B, Hake PW, O’Connor M, Burroughs TJ, Wong HR, Solomkin JS, Lentsch AB. Lung injury after hemorrhage is age-dependent: role of peroxisome proliferator activated receptor g. Crit. Care Med. 37: 1978-1987, 2009.

Wheeler DS, Zingarelli B, Wheeler WJ, Wong HR. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat. Inflamm. Allergy Drug Discov. 3: 96-112, 2009.

Wang X, Zingarelli B, O’Connor M, Zhang P, Adeyemo A, Wang Y, Kranias EG, Fan GC. Overexpression of Hsp20 prevents endotoxin-induced myocardial dysfunction and apoptosis via inhibition of NF-kB activation.J. Mol. Cell Cardiol. 47: 382-390, 2009.

Kaplan JM, Denenberg A, Monaco M, Gunn B, Nowell M, Wong H, Zingarelli B. Peroxisome Proliferator activated receptor-g activity in children with septic shock. Intensive Care Med., 2009 Sep 17. [Epub ahead of print].

Presentations, Most Recent

Is PPARg a novel target for moderating sepsis induced inflammation? The 34th International Educational and Scientific Symposium of The Society of Critical Care Medicine, January 15-19, 2005, Phoenix, Arizona, U.S.A.

Epigallocatechin-3-gallate and Inflammation Related Injury. April 2, 2005. Experimental Biology 2005, San Diego, California. International Life Sciences Institute sponsored satellite program on Functional Foods for Health Promotion: Impact on the Inflammatory Response.

PPARg and PPARg ligands. The 35th International Educational and Scientific Symposium of The Society of Critical Care Medicine, January 7-11, 2006, San Francisco, California.

Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) as Therapeutics Targets in Shock and Inflammation. 6th Congress of the International Federation of Shock Societies and 31th Annual Conference on Shock, June 28-July 2, 2008, Cologne, Germany.

Hot molecules in sepsis: PPARg and PPARg ligands. The 38th International Educational and Scientific Symposium of The Society of Critical Care Medicine, January 31-February 4, 2009, Nashville, Tennessee.

PPARg and NF-xB inhibition. The 32nd Annual Conference on Shock, June 6-9, 2009, San Antonio, Texas.

Translational Research - from the bench. Current Concepts in Pediatric Critical Care, Pre-Congress Educational Session of the 39th International Educational and Scientific Symposium of The Society of Critical Care Medicine, January 9, 2010, Miami, Florida.

PPARg: facing the immune dilemma with activation and suppression. The 33rd Annual Conference on Shock, June 12-15, 2010, Portland, Oregon.

Professional Organization Memberships

Shock Society
Women’s Faculty Association, Cincinnati Children’s Hospital Medical Center
American Gastroenterology Society
Society for Pediatric Research
American Heart Association and American Stroke Association
Society of Critical Care Medicine

Professional or Scientific Committees and Editorial Boards

Editorial Board Member of Shock, official journal of the Shock Society. 2002 - present
President, Women’s Faculty Association, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. 2003 - 2004
Treasurer, Shock Society. 2007 - present
Member, National Institutes of Health, Surgery, Anesthesiology and Trauma (SAT) Study Section. 2008 - 2012